GAMA Healthcare has announced the international launch of Rediroom, a portable isolation solution, which has already been successfully adopted by NHS hospitals.
Rediroom, launched in 2020, is a mobile cart that expands into a HEPA air-filtered isolation room with hands-free entry in five minutes, providing a flexible solution to increasing isolation capacity in response to outbreaks of infection, suspected or unconfirmed infections, and the ability to isolate patients anywhere, including multi-occupancy wards. This reduces the risk of HCAIs that are spread through droplet and direct contact, including norovirus, seasonal flu, C. diff, and Methicillin resistant Staphylococcus aureus (MRSA).
Following initial sales to hospitals in Japan, GAMA is now launching the product internationally into further key geographies across Europe, MEA, Asia, the Americas and Oceania, and is in discussions with a number of potential partners. The Company will be exhibiting at MEDICA, a world leading medical trade fair taking place from 15 – 18 November 2021 in Düsseldorf, Germany.
The NHS has been a key customer for Rediroom thus far, with 30 different UK hospitals having adopted the product, which has represented a 1% increase in isolation capacity for the entirety of the NHS in England. Isolation of infected or colonized patients is a measure utilised to reducing transmission of microorganisms between patients. Reducing transmission (via increased isolation capacity) can be linked to reducing the risk of patients acquiring HCAIs. Health economics data published in the Journal of Hospital Infection in July 2021 found that the adoption of Rediroom was likely to be a cost-effective strategy for the NHS if it reduced the chances of an HCAI by at least 16.5%.
Importantly, Rediroom is designed to isolate against diseases spread through droplet and direct contact, rather than through aerosol, meaning that the protection provided by Rediroom is most effective for diseases such as norovirus, seasonal flu, C. diff, and MRSA.
Guy Braverman, Joint-CEO, GAMA Healthcare, said: “We have been delighted by the successful roll-out and the adoption of Rediroom by the NHS, having received almost 400 orders less than two years after launching the product. The NHS has been a key customer thus far, where Rediroom has increased the isolation capacity of each purchasing hospital by an average of 5%, and produced excellent results during the pandemic.
“The reception to Rediroom from the hospitals using it, and from those who have evaluated the product, has been highly positive...Following the success in the UK and Japan, we are now focused on the international launch of Rediroom in target overseas markets, and are in discussions with a number of potential new partners to help us accelerate the growth of Rediroom across the world.”
